Hongmei Cui, Kinsie Arnst, Duane D. Miller and Wei Li* Pages 6573 - 6595 ( 23 )
Paclitaxel (PTX) is a first-line drug for late-stage non-small cell lung cancer (NSCLC) patients who do not benefit from targeted therapy or immunotherapy. However, patients invariably develop resistance to PTX upon prolonged treatments. Although diverse mechanisms leading to PTX resistance have been well-documented in the literature, strategies to overcome PTX resistance in NSCLC based on these mechanisms are still challenging. In this article, we reviewed recent advancements elucidating major mechanisms of PTX resistance in NSCLC, including the overexpression of ABC transporters, alternations to tubulin structures, and the involvement of cytokines, miRNAs, kinase signaling pathways, and epithelial-mesenchymal transition. Potential markers of PTX resistance or PTX response that could help to direct treatment decisions and restore cellular sensitivity to PTX were also discussed. Finally, we summarized the corresponding strategies to overcome PTX resistance in NSCLC cells, which might provide new insights into clinical trials and benefit lung cancer patients in the future.
Paclitaxel resistance, NSCLC, P-gp, Microtubule, Cancer cell survival and apoptosis, EMT, Activated kinase pathway.
Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163